Detalhe da pesquisa
1.
Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study.
Ann Oncol
; 34(8): 670-680, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37211044
2.
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
Ann Oncol
; 34(9): 783-795, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37302750
3.
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Ann Oncol
; 34(10): 885-898, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37597578
4.
A compact-rigid multi-analyser for energy and angle filtering of high-resolution X-ray experiments. Part 1. Principles and implementation.
J Synchrotron Radiat
; 30(Pt 1): 111-125, 2023 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36601931
5.
A compact-rigid multi-analyser for energy and angle filtering of high-resolution X-ray experiments. Part 2. Efficiency of a single-crystal-comb.
J Synchrotron Radiat
; 30(Pt 1): 126-136, 2023 Jan 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36601932
6.
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Ann Oncol
; 30(6): 921-926, 2019 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30778520
7.
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Ann Oncol
; 30(6): 927-933, 2019 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30903140
8.
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study.
Eur J Neurol
; 26(2): 363-370, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30298572
9.
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
Ann Oncol
; 29(1): 170-177, 2018 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29045543
10.
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types.
Ann Oncol
; 29(10): 2121-2128, 2018 10 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30165419
11.
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.
Ann Oncol
; 27(10): 1867-73, 2016 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27484801
12.
Home management of acute medical complications in cancer patients: a prospective pilot study.
Support Care Cancer
; 24(5): 2129-2137, 2016 May.
Artigo
Inglês
| MEDLINE | ID: mdl-26556209
13.
Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypeswaiting for TAILORx and RxPONDER.
Ann Oncol
; 26(1): 70-74, 2015 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-25355719
14.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
Ann Oncol
; 31(12): 1623-1649, 2020 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32979513
15.
Predicting response and survival in chemotherapy-treated triple-negative breast cancer.
Br J Cancer
; 111(8): 1532-41, 2014 Oct 14.
Artigo
Inglês
| MEDLINE | ID: mdl-25101563
16.
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
Ann Oncol
; 25(3): 552-563, 2014 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-24265351
17.
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B).
ESMO Open
; 9(3): 102388, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38442452
18.
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.
ESMO Open
; 9(3): 102903, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38452436
19.
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).
Ann Oncol
; 29(8): 1634-1657, 2018 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30032243
20.
OSNA Total Tumor Load for the Prediction of Axillary Involvement in Breast Cancer Patients: Should We use Different Thresholds According to the Intrinsic Molecular Subtype? MOTTO Study.
Clin Pathol
; 16: 2632010X231183693, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37534372